Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases.
Acute respiratory distress syndrome
COVID-19
Cytokine storm
Exosome
Mesenchymal stem cells
SARS-CoV-2
Journal
Inflammation and regeneration
ISSN: 1880-9693
Titre abrégé: Inflamm Regen
Pays: England
ID NLM: 101479577
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
05
2020
accepted:
08
06
2020
entrez:
26
6
2020
pubmed:
26
6
2020
medline:
26
6
2020
Statut:
epublish
Résumé
The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19) and the ensuing worldwide pandemic. The spread of the virus has had global effects such as activity restriction, economic stagnation, and collapse of healthcare infrastructure. Severe SARS-CoV-2 infection induces a cytokine storm, leading to acute respiratory distress syndrome (ARDS) and multiple organ failure, which are very serious health conditions and must be mitigated or resolved as soon as possible. Mesenchymal stem cells (MSCs) and their exosomes can affect immune cells by inducing anti-inflammatory macrophages, regulatory T and B cells, and regulatory dendritic cells, and can inactivate T cells. Hence, they are potential candidate agents for treatment of severe cases of COVID-19. In this review, we report the background of severe cases of COVID-19, basic aspects and mechanisms of action of MSCs and their exosomes, and discuss basic and clinical studies based on MSCs and exosomes for influenza-induced ARDS. Finally, we report the potential of MSC and exosome therapy in severe cases of COVID-19 in recently initiated or planned clinical trials of MSCs (33 trials) and exosomes (1 trial) registered in 13 countries on ClinicalTrials.gov.
Identifiants
pubmed: 32582401
doi: 10.1186/s41232-020-00121-y
pii: 121
pmc: PMC7306412
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
14Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsThe authors declare that they have no competing interests.
Références
Clin Microbiol Infect. 2020 Jun;26(6):767-772
pubmed: 32304745
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Regen Ther. 2019 Sep 20;11:269-281
pubmed: 31667206
Regen Ther. 2020 May 15;14:252-261
pubmed: 32455155
Sci Rep. 2020 Mar 9;10(1):4290
pubmed: 32152403
Science. 2020 Mar 27;367(6485):1412-1413
pubmed: 32217705
Aging Dis. 2020 Mar 9;11(2):216-228
pubmed: 32257537
J Clin Invest. 2020 May 1;130(5):2202-2205
pubmed: 32217834
Semin Immunopathol. 2017 Jul;39(5):529-539
pubmed: 28466096
J Infect Dis. 2019 Jan 7;219(2):186-196
pubmed: 30085072
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Stem Cell Rev Rep. 2020 Jun;16(3):427-433
pubmed: 32281052
Cell Tissue Res. 2019 May;376(2):257-271
pubmed: 30635774
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Stem Cells Transl Med. 2019 Mar;8(3):271-284
pubmed: 30394698
Stem Cells. 2020 Jan;38(1):15-21
pubmed: 31381842
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Clin Infect Dis. 2020 Mar 12;:
pubmed: 32161940
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32176772
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
J Extracell Vesicles. 2019 Apr 29;8(1):1609206
pubmed: 31069028
Engineering (Beijing). 2020 Feb 28;:
pubmed: 32292627
Stem Cells Transl Med. 2017 Aug;6(8):1730-1739
pubmed: 28714557
Inflamm Regen. 2019 Sep 9;39:18
pubmed: 31516638
J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324
pubmed: 32238757
Ann Intern Med. 2020 May 5;172(9):577-582
pubmed: 32150748
Cytotherapy. 2006;8(4):315-7
pubmed: 16923606
JAMA. 2020 Feb 7;:
pubmed: 32031570
JAMA. 2020 Apr 22;:
pubmed: 32320003
J Infect. 2020 Jun;80(6):607-613
pubmed: 32283152
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Stem Cells Transl Med. 2020 Jan;9(1):39-46
pubmed: 31411820
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094
J Gastroenterol. 2017 Feb;52(2):129-140
pubmed: 27631592
J Autoimmun. 2020 Jul;111:102452
pubmed: 32291137
Inflamm Regen. 2017 Jul 3;37:16
pubmed: 29259715
Int J Hematol. 2016 Feb;103(2):155-64
pubmed: 26759322
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Extracell Vesicles. 2019 Aug 1;8(1):1648167
pubmed: 31489144
Biores Open Access. 2019 Nov 11;8(1):185-199
pubmed: 31720090